首页> 外文期刊>European urology >Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
【24h】

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells

机译:卡巴他赛在去势抵抗性前列腺癌中的功效与循环肿瘤细胞中AR-V7的存在无关

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from patients with metastatic castration-resistant prostate cancer (mCRPC) was recently demonstrated to be associated with resistance to abiraterone and enzalutamide. Cabazitaxel might, however, remain effective in AR-V7-positive patients.
机译:背景:最近已证明,来自转移性去势抵抗性前列腺癌(mCRPC)患者的循环肿瘤细胞(CTC)中的雄激素受体剪接变体7(AR-V7)与对阿比特龙和enzalutamide的耐药有关。然而,卡巴他赛在AR-V7阳性患者中可能仍然有效。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号